Lots of interest (Q&A) on 4Q call | RGLS Message Board Posts


Regulus Therapeutics Inc.

  RGLS website

RGLS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  490 of 777  at  3/8/2018 7:47:39 AM  by

Aspector

The following message was updated on 3/8/2018 7:53:08 AM.

Lots of interest (Q&A) on 4Q call

Wedbush, Cowan, Leerink, Needham, Wells Fargo, BMO.
Interesting that some of the new directions in R&D include working with other companies technology to target outside the liver (LNP?), anti-infection/immunology opportunities, especially wrt use of biomarkers and clinical efficacy for earlier read-out of success. Wells Fargo asked about 24 week analysis of HERA, response was:
"Yes, the 24 week interim analysis is a blinded analysis, so the most likely situation I would guide investors to is that the data monitoring committee met and reviewed data from all patients through 24 weeks and instructed the sponsor to continue. We obviously dont want to break the blind in the study at the interim analysis.

There is a chance that trial could be wrapped up early by hitting the primary endpoint but that's not what we're powered to show. So, and then the 48 week data upon completion of that and data analysis well be reporting that. Once we are fully enrolled we can then provide (some) timeline to those milestones."
ATHENA expected to be presented at a medical conference 2H2018.
Overall, some delays to Alport recruitment due to logistics, but ADPKD advanced, R&D ideas show focus on early POC .


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 4  
   Views: 236 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
497 Re: Lots of interest (Q&A) on 4Q call biobull 0 4/17/2018 9:28:06 PM


Financial Market Data provided by
.
Loading...